To ablate or not to ablate? HSCs in the T cell driver's seat

Journal of Clinical Investigation

Volumn 117, Issue 2, 2007, Pages 306-310

  Anasetti, Claudio ^a   Mulé, James J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DENDRITIC CELL VACCINE; INTERLEUKIN 2; MELANOMA ANTIGEN 1; MELANOMA VACCINE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; DISSEMINATED CANCER; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; LYMPHOCYTOPENIA; MELANOMA; MEMORY T LYMPHOCYTE; MYELOABLATIVE CONDITIONING; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; VIRUS INFECTION; WHOLE BODY RADIATION;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE DEPLETION; NEOPLASMS; T-LYMPHOCYTES;

EID: 33846837642     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30973     Document Type: Review

References (58)

1. Lizee, G., Radvanyi, L.G., Overwijk, W.W., and Hwu, P. 2006. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin. Cancer Res. 12:4794-4803.
2. Finke, J.H., et al. 1993. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 53:5613-5616.
3. Wang, L.X., et al. 2005. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 65:10569-10577.
4. + T cells. J. Exp. Med. 202:907-912.
5. Mulé, J.J., Jones, F.R., Hellstrom, I., and Hellstrom, K.E. 1979. Selective localization of radiolabeled immune lymphocytes into syngeneic tumors. J. Immunol. 123:600-606.
6. Lugade, A.A., et al. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174:7516-7523.
7. Wang, L.X., Shu, S., and Plautz, G.E. 2005. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res. 65:9547-9554.
8. Dummer, W., et al. 2002. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110:185-192. doi:10.1172/JCI200215175.
9. Cho, B.K., Rao, V.P., Ge, Q., Eisen, H.N., and Chen, J. 2000. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J. Exp. Med. 192:549-556.
10. Petrus, M.J., Williams, J.F., Eckhaus, M.A., Gress, R.E., and Fowler, D.H. 2000. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol. Blood Marrow Transplant. 6:182-189.
11. +) T cells to the antitumor immune response. J. Exp. Med. 201:1591-1602.
12. Estin, C.D., Stevenson, U.S., Hellstrom, I., and Hellstrom, K.E. 1989. Cyclophosphamide potentiates the antitumor activity of v-p97NY. Cell. Immunol. 120:126-131.
13. + T cells. J. Clin. Invest. 117:492-501. doi:10.1172/JCI30414.
14. Nobusada, K., Kuhn, L., Pilon-Thomas, S.A., and Mulé, J.J. 2005. Adoptive immunotherapy combined with a dendritic cell-based vaccine results in the rejection of established tumor in a murine melanoma model. J. Immunother. 28:614.
15. Ma, J., et al. 2003. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur. J. Immunol. 33:2123-2132.
16. La Gruta, N.L., Driel, I.R., and Gleeson, P.A. 2000. Peripheral T cell expansion in lymphopenic mice results in a restricted T cell repertoire. Eur. J. Immunol. 12:3380-3386.
17. Ge, Q., Rao, V.P., Cho, B.K., Eisen, H.N., and Chen, J. 2001. Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/MHC epitopes and strength of their interaction with T cell receptors. Proc. Natl. Acad. Sci. U. S. A. 98:1728-1733.
18. Hu, H.M., Poehlein, C.H., Urba, W.J., and Fox, B.A. 2002. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 62:3914-3919.
19. Ge, Q., Palliser, D., Eisen, H.N., and Chen, J. 2002. Homeostatic T cell proliferation in a T cell-dendritic cell coculture system. Proc. Natl. Acad. Sci. U. S. A. 99:2983-2988.
20. Lou, Y., et al. 2004. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 64:6783-6790.
21. Oehen, S., and Brduscha-Riem, K. 1999. Naive cytotoxic T lymphocytes spontaneously acquire effector function in lymphocytopenic recipients: a pitfall for T cell memory studies? Eur. J. Immunol. 29:608-614.
22. Kieper, W.C., and Jameson, S.C. 1999. Homeostatic expansion and phenotypic conversion of naive T cells in response to self peptide/MHC ligands. Proc. Natl. Acad. Sci. U. S. A. 96:13306-13311.
23. + T cells in lymphopenic hosts. Immunity. 11:183-190.
24. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U. S. A. 102:9571-9576.
25. + T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211:214-224.
26. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 11:748-756.
27. Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:708-712.
28. He, H., et al. 2006. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J. Transl. Med. 4:24.
29. Dudley, M.E., and Rosenberg, S.A. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer. 3:666-675.
30. Dudley, M.E., et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
31. Dudley, M.E., et al. 2002. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25:243-251.
32. Asavaroengchai, W., Kotera, Y., Koike, N., Pilon-Thomas, S., and Mulé, J.J. 2004. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells. Biol. Blood Marrow Transplant. 10:524-533.
33. Bacci, A., et al. 2002. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J. Immunol. 168:2904-2913.
34. Asavaroengchai, W., Kotera, Y., and Mulé, J.J. 2002. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. U. S. A. 99:931-936.
35. Moyer, J.S., Maine, G., and Mulé, J.J. 2006. Early vaccination with tumor lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol. Blood Marrow Transplant. 12:1010-1019.
36. Ge, Q., Hu, H., Eisen, H.N., and Chen, J. 2002. Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. Proc. Natl. Acad. Sci. U. S. A. 99:2989-2994.
37. + T cells. Immunity. 22:259-270.
38. Leen, A.M., et al. 2005. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann. N. Y. Acad. Sci. 1062:104-115.
39. Bollard, C.M., et al. 2006. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk. Lymphoma. 47:837-842.
40. Leen, A.M., et al. 2006. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12:1160-1166.
41. Riddell, S.R., Bleakley, M., Nishida, T., Berger, C., and Warren, E.H. 2006. Adoptive transfer of allogeneic antigen-specific T cells. Biol. Blood Marrow Transplant. 12:9-12.
42. Riddell, S.R., and Greenberg, P.D. 1997. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev. Med. Virol. 7:181-192.
43. Kwak, L.W., Neelapu, S.S., and Bishop, M.R. 2004. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin. Oncol. 31:37-46.
44. Neelapu, S.S., et al. 2005. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant. 36:315-323.
45. Rapoport, A.P., et al. 2005. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11:1230-1237.
46. + T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12:335-341.
47. Tuma, R.A., Giannino, R., Guirnalda, P., Leinr, I., and Pamer, E.G. 2002. Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus. J. Clin. Invest. 100:1493-1501.
48. Farrell, A. 2006. Defeating T-cell fatigue in HIV. Nat. Med. 12:1124-1125.
49. Overwijk, W.W., et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198:569-580.
50. Collin, M.P., et al. 2006. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J. Exp. Med. 203:27-33.
51. Matte, C.C., et al. 2004. Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10:987-992.
52. Reddy, P., et al. 2005. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat. Med. 11:1244-1249.
53. Feng, B., et al. 2000. Development of mouse dendritic cells from lineage-negative c-kit(low) pluripotent hemopoietic stem cells in vitro. Stem Cells. 18:53-60.
54. Ginhoux, F., et al. 2006. Langerhans cells arise from monocytes in vivo. Nat. Immunol. 7:265-273.
55. Merad, M., et al. 2004. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat. Med. 10:510-517.
56. + T cells. J. Immunol. 175:6428-6435.
57. Gattinoni, L., Powell, D.J., Rosenberg, S.A., and Restifo, N.P. 2006. Adoptive immunotherapy of cancer: building on success. Nat. Rev. Immunol. 6:383-393.
58. Morgan, R.A., et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 314:126-129.